MedTrace Logo

Plasma Purification and Chronic Hepatitis B

NCT04518553 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 230

Last updated 2021-03-17

No results posted yet for this study

Summary

To compare the efficacy of nucleoside analogues （HA） alone and plasma purification +HA in reducing HBV viral load.

Conditions

Interventions

DRUG

active comarator using antiviral drug of nucleoside analogues

using antiviral drug of nucleoside analogues without additional active interference to control Hepatitis B virus.

DEVICE

HA+purification

Based on antiviral drug of nucleoside analogues, plasma purification is added to control hepatitis B virus every three months. After three months, plasma purification will continue if hepatitis B virus DNA titer is still higher than cut-off normal value. plasma purification process lasts 2.5-3 hours each session.

Sponsors & Collaborators

  • Shanghai Pudong Hospital

    lead OTHER

Principal Investigators

  • Hui Min Jin, MD · Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-23
Primary Completion
2023-09-01
Completion
2023-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04518553 on ClinicalTrials.gov